GlassScriptPhysician profile
Angela Mehler
NPI 1316362833
$5,126.94
in general payments reported to CMS, 2019-2025
21 companies · $4,182 in 2025
The $4,182 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $65.92 · 2023: $21.84 · 2024: $857 · 2025: $4,182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,684 · Honoraria: $1,280 · Travel and Lodging: $1,084 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,684.46 |
| Honoraria | $1,280.00 |
| Travel and Lodging | $1,084.41 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $2,995.12 | 2024-2025 | Brixadi |
| Abbvie INC. | $429.46 | 2022-2025 | |
| Alkermes, INC. | $309.95 | 2024-2025 | Vivitrol, Aristada, Lybalvi |
| Indivior INC. | $260.29 | 2024-2025 | Sublocade |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $225.89 | 2024-2025 | Caplyta |
| Axsome Therapeutics, INC. | $217.51 | 2024-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $138.97 | 2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $134.18 | 2024-2025 | Uzedy, Austedo Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.24 | 2024-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $70.38 | 2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lilly USA, LLC | $56.69 | 2022-2024 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $24.42 | 2024 | |
| Supernus Pharmaceuticals, INC. | $20.63 | 2024 | Qelbree |
| Phathom Pharmaceuticals, INC. | $20.40 | 2024 | Voquezna |
| Lundbeck LLC | $19.76 | 2025 | Rexulti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $15.70 | 2025 | Cobenfy |
| Hikma Pharmaceuticals USA | $15.54 | 2024 | Kloxxado |
| Glaxosmithkline, LLC. | $15.48 | 2024 | Shingrix, Arexvy |
| Novo Nordisk INC | $15.06 | 2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $14.20 | 2024 | Breztri |
| Exact Sciences Corporation | $13.07 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Mehler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.